Oral News and Research

RSS

New way to accurately test for peanut allergy

Researchers from Murdoch Childrens Research Institute and the University of Melbourne have identified a new way to accurately test for peanut allergy.

21 Mar 2012

First Edition: March 20, 2012

Today's headlines include reports about the new GOP budget proposal, to be unveiled today by House Budget Committee Chairman Paul Ryan, R-Wis.

20 Mar 2012

Positive data from XENTION's XEN-D0103 phase 1 trial on AF

XENTION LTD, the Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs, reported positive data today from a phase 1 trial of XEN-D0103 administered orally.

20 Mar 2012

TB Alliance launches new combination drug trial

In an ambitious effort to stem the dangerous tide of tuberculosis (TB) and deadly drug-resistant TB around the world, TB Alliance today announced that it has launched a first-of-its-kind clinical trial to test a novel drug combination – in both patients who have TB and those who have multidrug-resistant TB (MDR-TB).

19 Mar 2012

NIH awards Avaxia $1.5M Phase II SBIR grant to develop antibody therapeutic for IBD

Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, is proud to announce that it has received a second round of funding from the National Institutes of Health for its work in inflammatory bowel disease.

19 Mar 2012

High Court says no to allowing cameras to broadcast the health law arguments

This announcement, made Friday, is consistent with tradition. However, the court will make available same-day audio of the oral arguments because of "extraordinary public interest."

19 Mar 2012

Ampio completes partial planned interim review in Optina trial for diabetic macular edema

Ampio Pharmaceuticals, Inc., a biopharmaceutical company conducting clinical trials on its three lead drugs (Zertane completed two phase III studies, Ampion-completed proof of concept studies and Optina), licensing distribution of these drugs and engaged in further drug development, today announced that it completed the planned interim review of the first 50% of patients enrolled in the Optina trial for diabetic macular edema.

19 Mar 2012

PaxVax announces FDA acceptance of IND for PXVX-0200 cholera vaccine

PaxVax Corporation, developer of innovative and socially responsible oral vaccines against infectious diseases, announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application for its single-dose oral cholera vaccine, clearing the way to begin clinical trials. The company intends to begin Phase 3 trials later this year.

19 Mar 2012

First Edition: March 19, 2012

Today's headlines reflect the anticipation and anxiety that surrounds the Supreme Court's upcoming health law oral arguments.

19 Mar 2012

Sides counting down to Supreme Court health reform arguments

Can the government really tell us what to buy? Federal judges have come down on both sides of the question, leaving it to the Supreme Court to sort out. The justices are allotting an unusually long period, six hours over three days, beginning March 26, to hear arguments challenging the law's constitutionality. Their ruling, expected in June, is shaping up as a historic moment in the century-long quest by reformers to provide affordable health care for all.

19 Mar 2012

Oral BRAF inhibitor can extend survival to 16 months for patients with MM

An international team of researchers from the United States and Australia, including researchers at Moffitt Cancer Center in Tampa, Fla., have found that the oral BRAF inhibitor vemurafenib (PLX4032) when tested in a phase II clinical trial offered a high rate of response in patients with previously treated metastatic melanoma and who had the BRAF mutation.

17 Mar 2012

Administration lawyers shift Supreme Court arguments to draw support from key justices

Part of their challenge is to convince the justices the health care marketplace is "unique." Meanwhile, Health and Human Services Secretary Kathleen Sebelius talked to Democratic lawmakers on Capitol Hill about "alternatives" to the individual mandate if it were struck down. And The Wall Street Journal reports the oral arguments before the Supreme Court may be the hottest show in Washington.

17 Mar 2012

New Aspen Dental office to open on March 29 in Walpole, MA

Patients looking for a dentist in Walpole, MA now have a new dental care provider option with the opening of a new Aspen Dental office this month. The new practice, which opens on Thursday, March 29 in the Walpole Mall at 116 Providence Hwy., will provide dental services that range from dentures and preventive care to general dentistry and restoration.

17 Mar 2012

New Aspen Dental office to open on March 29 in Spring Hill, FL

Patients looking for a dentist in Spring Hill, FL now have a new dental care provider option with the opening of a new Aspen Dental office this month. The new practice, which opens on Thursday, March 29 in the Spring Hill at 1525 Commercial Way, will provide dental services that range from dentures and preventive care to general dentistry and restoration.

17 Mar 2012

Positive data from VBL Therapeutics' VB-201 Phase 2 study on psoriasis, atherosclerosis

VBL Therapeutics, a clinical stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that a Phase 2 sub-study of VB-201 in moderate to severe psoriasis patients with cardiovascular risk has successfully achieved its primary endpoint demonstrating a statistically significant reduction in vascular inflammation associated with atherosclerotic lesions as measured by PET-CT imaging.

17 Mar 2012